<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="214">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614012</url>
  </required_header>
  <id_info>
    <org_study_id>IMMUNO-COVID19</org_study_id>
    <nct_id>NCT04614012</nct_id>
  </id_info>
  <brief_title>Hyperimmune Plasma for Patients With COVID-19</brief_title>
  <acronym>IMMUNO-COVID19</acronym>
  <official_title>The Use of Hyperimmune Plasma for the Treatment of COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANNA FALANGA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which&#xD;
      originated in Wuhan, China, has become a major concern all over the world.&#xD;
&#xD;
      Convalescent plasma or immunoglobulins have been used as a last resort to improve the&#xD;
      survival rate of patients with SARS whose condition continued to deteriorate despite&#xD;
      treatment with pulsed methylprednisolone. Moreover, several studies showed a shorter hospital&#xD;
      stay and lower mortality in patients treated with convalescent plasma than those who were not&#xD;
      treated with convalescent plasma. Evidence shows that convalescent plasma from patients who&#xD;
      have recovered from viral infections can be used effectively as a treatment of patients with&#xD;
      active disease. To date, no specific treatment has been proven to be effective. The&#xD;
      investigators plan to treat critical Covid-19 patients with hyperimmune plasma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apheresis from recovered donors will be performed with a cell separator device , with 500-600&#xD;
      mL of plasma obtained from each donor. Donors are males and womens , age 18 yrs or more,&#xD;
      evaluated for transmissible diseases according to the italian law. Adjunctive tests will be&#xD;
      for hepatitis A virus, hepatitis E virus and Parvovirus B-19. All donors will be tested for&#xD;
      the Covid-19 neutralizing title. Each plasma bag obtained from plasmapheresis will be&#xD;
      immediately divided in two units and frozen according to the national standards and stored&#xD;
      separately.&#xD;
&#xD;
      Based on experience published in literature 250-300 mL of convalescent plasma will be used to&#xD;
      treat each of the recruited patients at most 3 times over 5 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2020</start_date>
  <completion_date type="Anticipated">July 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Longitudinal assessment of COVID-19 patients treated with hyperimmune plasma</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>within 30 days</time_frame>
    <description>death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to extubation</measure>
    <time_frame>within 7 days</time_frame>
    <description>days since intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of intensive care unit stay</measure>
    <time_frame>within 7 days</time_frame>
    <description>days from entry to exit from ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospitalization</measure>
    <time_frame>within 30 days</time_frame>
    <description>days from entry to exit from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune response</measure>
    <time_frame>at days 1, 3 and 7</time_frame>
    <description>neutralizing title</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral load</measure>
    <time_frame>at days 1, 3 and 7</time_frame>
    <description>naso-pharyngeal swab and BAL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>hyperimmune plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with hyperimmune plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>treated with hyperimmune plasma</intervention_name>
    <description>administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5</description>
    <arm_group_label>hyperimmune plasma</arm_group_label>
    <other_name>hyperimmune plasma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;=18 yrs&#xD;
&#xD;
          -  positive for reverse transcription polymerase chain reaction (RT-PCR) severe acute&#xD;
             respiratory syndrome (SARS)-CoV-2&#xD;
&#xD;
          -  Acute respiratory distress syndrome (ARDS) moderate to severe, according to Berlin&#xD;
             definition, lasting less than10 days&#xD;
&#xD;
          -  Polymerase chain reaction (PCR) positive&#xD;
&#xD;
          -  signed informed consent unless unfeasible for the critical condition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  proven hypersensitivity or allergic reaction to hemoderivatives or immunoglobulins&#xD;
&#xD;
          -  consent denied&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Falanga</last_name>
    <phone>+39 0352674776</phone>
    <email>afalanga@asst-ph23.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anna Falanga</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Falanga</last_name>
      <email>afalanga@asst-pg23.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>A.O. Ospedale Papa Giovanni XXIII</investigator_affiliation>
    <investigator_full_name>ANNA FALANGA</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>covid19</keyword>
  <keyword>Hospitalized patients</keyword>
  <keyword>Hyperimmune plasma</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

